Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In summary, the differential expression of the immunomodulatory molecule YKL-40 may affect the treatment efficacy of PI3K/AKT-based pathway inhibitors in glioblastoma.
|
29729901 |
2018 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Previous studies have demonstrated that glioblastoma stem cells give rise to endothelial cells through an YKL-40 influence.
|
28430288 |
2017 |
Glioblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Phospho-c-Jun activation by Anisomycin treatment in primary glioblastoma-derived cells attenuates the aggressive features of mesenchymal glioblastomas and leads to promoter methylation and downregulation of key mesenchymal genes (CD44, MMP9 and CHI3L1).
|
28036297 |
2017 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Meta-analysis of those studies showed that high YKL-40 expression was associated with worse overall survival in glioblastoma patients (HR = 1.46, 95%CI 1.33-1.61, P < 0.001).
|
27090900 |
2017 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that the STAT3 pathway is associated with the mTOR downstream pathway mediated by YKL-40 protein, and the combination therapy of the STAT3 inhibitor and rapamycin could be worth developing as a novel therapeutic approach against TMZ-resistant relapsed gliomas.
|
28031240 |
2017 |
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Meta-analysis of those studies showed that high YKL-40 expression was associated with worse overall survival in glioblastoma patients (HR = 1.46, 95%CI 1.33-1.61, P < 0.001).
|
27090900 |
2017 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Previous studies have demonstrated that glioblastoma stem cells give rise to endothelial cells through an YKL-40 influence.
|
28430288 |
2017 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Findings presented in our study showed that increased mRNA level of CHI3L1 could be associated with the progression of astrocytoma and poor patient survival not only for glioblastoma, but for lower grade astrocytoma tumors as well.
|
27121858 |
2016 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Both our case reports were adult males who developed extra-CNS, YKL-40-positive metastases at lymph nodes, lung and subcutaneous sites, after 86 and 24 months from initial diagnosis of GBM.
|
26212701 |
2016 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Stepwise multivariate Cox proportional hazards models were used, and the prognostic factors to significantly impact OS were: PFS < 54 weeks (HR: 5.86; CI: 3.02-11.33; p = 0.00); radiotherapy (HR: 0.34; CI: 0.18-0.60; p = 0.00); radio- and chemotherapy (HR: 0.05; CI: 0.03-0.10; p = 0.0), and YKL-40+ GBs (HR: 1.61; CI: 1.28-2.31; p = 0.01).
|
27179219 |
2016 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We measured CHI3L1 expression with quantitative real time-polymerase chain reaction (qRT-PCR) in the cohort of 98 patients with different grade glioma: 10 grade I pylocytic astrocytomas, 30 grade II diffuse astrocytomas, 20 grade III anaplastic astrocytomas, and 38 grade IV astrocytomas (glioblastomas).
|
27121858 |
2016 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate, in a small series of three GCAs, the expression of mesenchymal/radioresistance-associated biomarkers [such as chitinase-3-like protein 1 (YKL-40), hepatocyte growth factor receptor (c-Met), and caveolin 1 (Cav1)] that could contribute to the poor outcome associated with this glioma subgroup.
|
26845757 |
2016 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Both our case reports were adult males who developed extra-CNS, YKL-40-positive metastases at lymph nodes, lung and subcutaneous sites, after 86 and 24 months from initial diagnosis of GBM.
|
26212701 |
2016 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Beyond known key players for GBM such as ERBB2, PMS2, or CHI3L1, we identified over 50 genes that have not been associated to GBM so far.
|
25537509 |
2015 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, YKL‑40 may be a novel key molecule in addition to MGMT, that is responsible for TMZ resistance in glioblastoma cell lines and could be a new target to overcome TMZ resistance in recurrent glioblastomas in the future.
|
24842123 |
2014 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
YKL-40 staining in situ was more abundant in glioblastoma tissue than in anaplastic astrocytoma, with the lowest level in normal brain tissue.
|
25629266 |
2014 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our gene analysis revealed that in general, YKL40 mRNA in glioma patients was over-expressed versus normal brain.
|
25629266 |
2014 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
YKL-40 staining in situ was more abundant in glioblastoma tissue than in anaplastic astrocytoma, with the lowest level in normal brain tissue.
|
25629266 |
2014 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, YKL‑40 may be a novel key molecule in addition to MGMT, that is responsible for TMZ resistance in glioblastoma cell lines and could be a new target to overcome TMZ resistance in recurrent glioblastomas in the future.
|
24842123 |
2014 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this paper, the authors' goal was to evaluate the prognostic value of YKL-40 expression as a prognostic factor for glioblastomas and to compare its validity to the already known MGMT.
|
22655594 |
2012 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Fitting models with and without YKL-40 highlights a subgroup of patients who have glioblastoma (GBM) diagnosis but appear to have better prognosis than the typical GBM patient.
|
22495652 |
2012 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Fitting models with and without YKL-40 highlights a subgroup of patients who have glioblastoma (GBM) diagnosis but appear to have better prognosis than the typical GBM patient.
|
22495652 |
2012 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
YKL-40 up-regulated VEGF expression in glioblastoma cell line U87, and both YKL-40 and VEGF synergistically promote endothelial cell angiogenesis.
|
21385870 |
2011 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Although YKL-40 expression is up-regulated in glioblastoma multiforme, its regulation and functions in nontransformed cells of the central nervous system are widely unexplored.
|
21953450 |
2011 |
Glioma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Thus, targeting the CHI3L1 molecule may be a potential therapeutic molecular target for gliomas.
|
20506295 |
2011 |